BioSenic Dividend

Dividend criteriumcontroles 0/6

BioSenic does not have a record of paying a dividend.

Belangrijke informatie

n/a

Dividendrendement

-74.8%

Terugkoop Rendement

Totaal aandeelhoudersrendement	-74.8%
Toekomstig dividendrendement	0%
Dividendgroei	n/a
Volgende betaaldatum dividend	n/a
Ex-dividenddatum	n/a
Dividend per aandeel	n/a
Uitbetalingsratio	n/a

Recente dividendupdates

Geen updates

Recent updates

Stabiliteit en groei van betalingen

Dividenden ophalen

Stabiel dividend: Insufficient data to determine if BIOS's dividends per share have been stable in the past.

Groeiend dividend: Insufficient data to determine if BIOS's dividend payments have been increasing.

Dividendrendement versus markt

BioSenic Dividendrendement versus markt

Hoe verhoudt BIOS dividendrendement zich tot de markt?
Segment	Dividendrendement
Bedrijf (BIOS)	n/a
Markt onderkant 25% (BE)	2.6%
Markt Top 25% (BE)	7.3%
Gemiddelde industrie (Biotechs)	1.5%
Analist prognose (BIOS) (tot 3 jaar)	0%

Opmerkelijk dividend: Unable to evaluate BIOS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Hoog dividend: Unable to evaluate BIOS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Winstuitkering aan aandeelhouders

Verdiendekking: Insufficient data to calculate BIOS's payout ratio to determine if its dividend payments are covered by earnings.

Contante uitbetaling aan aandeelhouders

Kasstroomdekking: Unable to calculate sustainability of dividends as BIOS has not reported any payouts.

BioSenic Dividend

Dividend criteriumcontroles 0/6

Belangrijke informatie

Recente dividendupdates

Recent updates

BioSenic S.A. Announces Executive Changes

Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO

Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office

Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide (Ato) Targeting Cgvhd

New major risk - Shareholder dilution

BioSenic S.A. to Report Fiscal Year 2023 Results on Jun 06, 2024

Biosenic S.A. Releases Details of Optimized Administration Approach Ahead of Planned Phase 3 Trial of OATO for Chronic Graft-Versus-Host Disease

BioSenic S.A. Patent Granted in Canada for Broader Protection of ATO Therapeutic Platform

BioSenic Presents New Phase 3 Data on JTA-004 to Treat Severe Osteoarthritis Pain at the 2024 OARSI World Congress

BioSenic Files for Additional Patent Protection Following New Clinical Evidence of Efficacy for JTA-004 in OA

Biosenic S.A. and Its Subsidiary Medsenic SAS Announces the Promotion of Carole Nicco to Chief Operating Officer

New major risk - Market cap size

BioSenic S.A. Performs Further Analysis of Its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide in cGvHD

BioSenic Publishes New Evidence of Beneficial Effects of Arsenic Treatment Supporting Clinical Trial for Systemic Sclerosis

New major risk - Market cap size

BioSenic S.A. Puts Phase IIb Allob Trial on Hold

BioSenic S.A. Appoints Yves Sagot as Independent Director

BioSenic Appoints Dr. Carole Nicco as Chief Scientific Officer

BioSenic S.A. Appoints Michel Wurm as Interim Chief Medical Officer

Less than half of directors are independent

BioSenic SA provides update on its autoimmune disease platform based on ATO (arsenic trioxide)

Less than half of directors are independent

Stabiliteit en groei van betalingen

Dividendrendement versus markt

Winstuitkering aan aandeelhouders

Contante uitbetaling aan aandeelhouders

Ontdek bedrijven met een sterk dividend